Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor

Clinical Cancer Research

Volumn 2, Issue 5, 1996, Pages 791-797

  Bunch, Roderick T ^a   Eastman, Alan ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; CISPLATIN; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CHO CELL; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; NONHUMAN; PRIORITY JOURNAL;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHO CELLS; CISPLATIN; CRICETINAE; DRUG SYNERGISM; ENZYME INHIBITORS; G2 PHASE; PROTEIN KINASE C; STAUROSPORINE;

EID: 0029992520     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Roberts, J. J., and Thomson, A. J. The mechanism of action of antitumor platinum compounds. Prog. Nucleic Acid Res. Mol. Biol., 22: 71-133, 1979.
2. Eastman, A. The formation, isolation, and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. & Ther., 34: 155-166, 1987.
3. Fraval, H. N. A., Rawlings, C. J., and Roberts, J. J. Increased sensitivity of UV-repair-deficient human cells to DNA-bound platinum products which, unlike thymine dimers, are not recognized by an endonuclease extracted from Micrococcus luteus. Mutat. Res., 51: 121-132, 1978.
4. Sorenson, C. M., and Eastman, A. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair-proficient and -deficient Chinese hamster ovary cells. Cancer Res., 48: 6703-6707, 1988.
5. Eastman, A., and Schulte, N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry, 27: 4730-4734, 1988.
6. Andrews, P. A., and Howell, S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (Cold Spring Harbor), 2: 35-43, 1990.
7. Demarcq, C., Bunch, R. T., Creswell, D., and Eastman, A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth & Differ., 5: 983-993, 1994.
8. Olivieri, G., and Micheli, A. Mitotic delay and repair in human lymphocytes. Mutat. Res., 122: 65-72, 1983.
9. Weinert, T. A., and Hartwell, L. H. The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science (Washington DC), 241: 317-322, 1988.
10. Rauth, A. M. Evidence for dark reactivation of ultraviolet light-damaged DNA in mouse L cells. Radiat. Res., 31: 121-138, 1967.
11. Lau, C. C., and Pardee, A. B. Mechanism by which caffeine potentiates lethality of nitrogen mustard Proc. Natl. Acad. Sci. USA, 79: 2942-2946, 1982.
12. Schlegel, R., and Pardee, A. B. Caffeine-induced uncoupling of mitosis from the completion of DNA replication in mammalian cells. Science (Washington DC), 232: 1264-1266, 1986.
13. Kimler, B. F., Leeper, D. B., Snyder, M. H., Rowley, R., and Schneiderman, M. H. Modification of radiation-induced division delay by caffeine analogues and dibutyryl cyclic AMP. Int J. Radiat. Biol., 41: 47-58, 1982.
14. Lamb, N. J. C., Cavadore, J-C., Labbe, J. C., Maurer, R. A., and Fernandez, A. Inhibition of cAMP-dependent protein kinase plays a role in the induction of mitosis and nuclear envelope breakdown in mammalian cells. EMBO J., 10: 1523-1533, 1991.
15. Schlegel, R., Belinsky, G. S., and Harris, M. O. Premature mitosis induced in mammalian cells by the protein kinase inhibitors 2-aminopurine and 6-dimethylaminopurine. Cell Growth & Differ., 1: 171-178, 1990.
16. 2-phase arrest in irradiated HeLa cells treated with staurosporine or caffeine. Radiat. Res., 140: 393-400, 1994.
17. Takahashi, I., Asano, K., Kawamoto, I., and Nakano, H. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. I. Screening, producing organism and fermentation. J. Antibiot. (Tokyo), 42: 564-570, 1989.
18. Takahashi, I., Saitoh, Y., Yoshida, M., Sano, H., Nakano, H., Morimoto, M., and Tamaoki, T. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J. Antibiot. (Tokyo), 42: 571-576, 1989.
19. Mizuno, K., Saido, T. C., Ohno, S., Tamaoki, T., and Suzuki, K. Staurosporine-related compounds, K252a and UCN-01, inhibit both cPKC and nPKC. FEBS Lett., 330: 114-116, 1993.
20. Seynaeve, C. M., Stetler-Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., and Worland, P. J. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res., 53: 2081-2086, 1993.
21. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell cycle distribution of human epidermoid carcinoma A431 cells. Cancer Chemother. Pharmacol., 33: 273-280, 1994.
22. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., and Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res., 51: 4888-4892, 1991.
23. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 32: 183-189, 1993.
24. Wang, Q., Worland, P. J., Clark, J. L., Carlson, B. A., and Sausville, E. A. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth & Differ., 6: 927-936, 1995.
25. Hill, D. L., Tillery, K. F., Rose, L. M., and Posey, C. F. Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. Cancer Chemother. Pharmacol., 33: 89-92, 1994.
26. Andreassen, P. R., and Margolis, R. L. 2-Aminopurine overrides multiple cell cycle checkpoints in BHK cells. Proc. Natl. Acad. Sci. USA, 89: 2272-2276, 1992.
27. Roberge, M., Tudan, C., Hung, S. M. F., Harder, K. W., Jirik, F. R., and Anderson, H. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res., 54: 6115-6121, 1994.
28. Grunicke, H. H. Protein kinase C modulation. Semin. Cancer Biol., 3: 351-360, 1992.
29. Basu, A., Teicher, B. A., and Lazo, J. S. Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J. Biol. Chem., 265: 8451-8457, 1990.
30. Isonishi, S., Andrews, P. A., and Howell, S. B. Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J. Biol. Chem., 265: 3623-3627, 1990.
31. 1 checkpoint-competent cells. Cancer Res., 55: 1639-1642, 1995
32. 2 delay. Cancer Res., 55: 1643-1648, 1995.
33. 2 checkpoint function in cancer cells with disrupted p53. J. Nat. Cancer Inst., in press, 1996.
34. Fan, S., Smith, M. L., Rivet, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
35. Larner, J. M., Lee, H., and Hamlin, J. L. Radiation effects on DNA synthesis in a defined chromosomal replicon. Mol. Cell. Biol., 14: 1901-1908, 1994.